Kras G12C Inhibitors In Nsclc Efficacy Resistance

Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022

Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor–Based Cellular Therapy

Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Tre

KSR induces RAS‐independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors

KRAS inhibitors: going noncovalent

Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node

Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of

Targeting the Small GTPase Superfamily through Their Regulatory Proteins

Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy

KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small ce

Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

Role of cytokines in combinatorial immunotherapeutics of non‐small cell lung cancer through systems perspective

Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharm

Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective obser

Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non‐squamous non‐small cell lung cancer pat

Targeted single‐cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis‐resistant state in hema

Mixed response to the first‐line treatment of KRAS G12C inhibitor, sotorasib, in non‐small cell lung cancer: A brief rep

Molecular testing for lung adenocarcinoma: Is it time to adopt a “plasma‐first” approach?

Advances in the treatment of KRAS G12C mutant non–small cell lung cancer

Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C‐mutated advanced non‐small cell lung c

Persistent lineage plasticity driving lung cancer development and progression

Drugging “undruggable” genes for cancer treatment: Are we making progress?

Fast proliferating and slowly migrating non‐small cell lung cancer cells are vulnerable to decitabine and retinoic acid

Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities

Ultrasensitive DNA Origami Plasmon Sensor for Accurate Detection in Circulating Tumor DNAs

Translational relevance of SOS1 targeting for KRAS‐mutant colorectal cancer

Differential Response and Resistance to KRAS-Targeted Therapy.

Understanding and targeting resistance mechanisms in cancer

RAS‐targeted cancer therapy: Advances in drugging specific mutations

Epigenetic regulation in lung cancer

2020 Innovation-Based Optimism for Lung Cancer Outcomes

Phase I Study of Afatinib and Selumetinib in Patients with <i>KRAS</i>-Mutated Colorectal, Non-Small Cell Lung, and Panc

A structural perspective on targeting the RTK /Ras/ MAP kinase pathway in cancer

Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors

Virtual clinical trial simulations for a novel KRAS^G12C inhibitor (ASP2453) in non‐small cell lung cancer

Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.

Current challenges and practical aspects of molecular pathology for non-small cell lung cancers

Targeting KRAS in pancreatic cancer: new drugs on the horizon

Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.

Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer.

Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line t

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.

Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies

Cholangiocarcinoma Targeted Therapies: Mechanisms of Action and Resistance.

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

Targeting KRAS in non-small cell lung cancer: recent progress and new approaches.

459MO Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and f

Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma

653O Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated

663P Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembroli

665P First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and c

1409P DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after

LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-smal

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.

1846MO Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant N

1989P Efficacy and safety of fulzerasib in patients (pts) with KRAS G12C-mutant non-small cell lung cancer (NSCLC): Upda

977MO Safety and efficacy of elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G

Resistance mutations and the blood–brain barrier: Key challenges in targeted treatment of brain metastatic non-small cel

Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C a

Unveiling the role of KRAS in tumor immune microenvironment.

TTP enhances the sensitivity of KRASG12C-mutated lung cancer cells to KRASG12C inhibitors by downregulating SLC7A11 and

Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non

AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.

WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer.

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.

A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by imm

MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.

Emerging landscape of KRAS inhibitors in cancer treatment.

Inducible Degradation of Target Proteins through a Tractable Affinity-Directed Protein Missile System

Successful Use of Sotorasib in a Patient With End-Stage Renal Disease on Dialysis With Metastatic Lung Adenocarcinoma: A

KRAS G12C Mutant Non–Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demog

KRAS mutations in non-small cell lung cancer: Translational aspects, current therapies and challenges for future researc

Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?

KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

MEK inhibitor resistance mechanisms and recent developments in combination trials.

Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) - biology, clinical results and future direction

Anticancer drug resistance: An update and perspective.

Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer

Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehen

HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2.

Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate us

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers

Synthetic approaches and clinical application of KRAS inhibitors for cancer therapy.

Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine

103TiP Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for meta

Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead

Screening and Validation of Molecular Targeted Radiosensitizers

KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer

KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in pa

Targeting KRAS G12C and G12S mutations in lung cancer: In silico drug repurposing and antiproliferative assessment on A5

LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small

Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer.

Oncogenic RAS promotes MYC protein stability by upregulating the expression of the inhibitor of apoptosis protein family

Endogenous oncogenic KRAS expression increases cell proliferation and motility in near-diploid hTERT RPE-1 cells.

Discovery of a tribenzophenazine analog for binding to the KRAS mRNA G-quadruplex structures in the cisplatin-resistant

Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors

Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International

KRAS G12C–Mutant Non–Small Cell Lung Cancer

Prognostic and Predictive Value of KRAS Mutation in NSCLC

KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC.

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)

IBS05.01 KRAS Mutant Lung Cancer

MO01.30 Trial in Progress: A Phase 1b Study of Sotorasib, a KRAS (G12C) Inhibitor, in Combination with other Anticancer

ES28.05 Combination Therapies to Maximize the Impact of KRAS-G12C Inhibitors

Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lun

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcomin

OA03.07 Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial

EP08.01-026 Influence of Brain Metastases on Survival of KRASG12C Mutated Stage IV Immune Checkpoint Inhibitor Treated N

PP01.41 Efficacy of Sotorasib Versus Standard Chemotherapy + Immunotherapy in KRAS G12C Mutated Lung Cancer: A Comparati

Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Progr

Toxicity From Sotorasib After Immune Checkpoint Inhibitors: A Note of Caution and Reflections of Future Advancements in

MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Sol

MA06.05 CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NS

P2.09-15 Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer

OA14.04 Efficacy and Safety of Olomorasib with Pembrolizumab + Chemotherapy as First-Line Treatment in Patients with KRA

OA08.02 Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001

MA02.06 Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 a

Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advan

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France S

Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asia

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations

Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)

Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.

Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line

On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma

Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice

Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized S

KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival

Clinical application of the AMOY 9-in-1 panel to lung cancer patients

KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing

Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program

The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?

Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G

Recent advances in therapeutic targeting of the KRAS pathway in cancer.

ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict i

Cyclopeptide RA-V from Rubia yunnanensis restores activity of Adagrasib against colorectal cancer by reducing the expres

Traitement par sotorasib en autorisation d’accès précoce dans le cancer pulmonaire non à petites cellules mutées KRAS G1

Exploiting metabolic vulnerabilities of Non small cell lung carcinoma

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-

The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer.

Efficacy and safety outcomes in patients receiving sotorasib for advanced KRAS G12C-mutated non-small cell lung cancer

Ornithine decarboxylase as a new target for improving the effect of KRAS-G12C inhibitors in non-small cell lung cancer c

Discovery of D3S-001, a highly potent and CNS-penetrant inhibitor of KRAS G12C with rapid and sustained target engagemen

Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C-Mutated Solid Tumors.

Emerging RAS Inhibitors: Heterocyclic and Spirocyclic Compounds in Cancer Therapeutics.

Preclinical Evaluation of [124I]-Sotorasib for the Imaging of Kirsten Rat Sarcoma G12C Mutant Tumors.

Targeting PI3Kα overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R.

High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models

Uncovering adagrasib resistance

At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC

A prime editor mouse to model a broad spectrum of somatic mutations in vivo

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies

KRASG12C inhibitor: combing for combination.

Efficacy and Safety of Olomorasib with Pembrolizumab+Chemotherapy as First Line Treatment in Patients with KRAS G12C-Mut

Acquired Resistance to KRASG12C Inhibition in Cancer.

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibit

Identification of novel peptide inhibitors for the KRas-G12C variant to prevent oncogenic signaling

Investigation of EGFR/pi3k/Akt signaling pathway in seminomas

Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocar

Cost-effectiveness of sotorasib versus adagrasib in previously treated KRAS G12C-mutated advanced NSCLC: a US healthcare

An evaluation of sotorasib for the treatment of patients with non–small cell lung cancer with KRASG12C mutations

Profiling opnurasib (JDQ-443) for the treatment of non-small cell lung cancer (NSCLC).

KRAS mutations in colorectal cancer: impacts on tumor microenvironment and therapeutic implications

Molecular therapeutic targets in non-small cell lung cancer

Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer.

Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.

Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics.

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer

A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors

SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling

DSTYK inhibition increases the sensitivity of lung cancer cells to T cell–mediated cytotoxicity

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the A

Pan-cancer analysis of clinical acquired resistance (AR) in BRAF-driven real-world cases

Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2

A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosin

The establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer

LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD

KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus che

Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers

Targeting KRAS G12C mutations in colorectal cancer

The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling

Addressing cancer signal transduction pathways with antisense and siRNA oligonucleotides

RADT-67. EVALUATING THE EFFICACY OF G12C-INHIBITORS IN CONJUNCTION WITH GAMMA KNIFE RADIOSURGERY FOR KRAS-MUTANT NSCLC B

Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the <i>KRAS G12C</i> Mutation

Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases

KRAS : Druggable at Last

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung C

Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report

Regulation of ferroptosis in KRas mutant cancer cells

Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells

A novel anticancer natural product SP09 selectively targets KRAS-mutant NSCLC through LKB1/AMPK/mTOR modulation: implica

Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance

Non–Small Cell Lung Cancer as a Precision Oncology Paradigm: Emerging Targets and Tumor Mutational Burden (TMB)

Genetic mechanisms of resistance to targeted KRAS inhibition

The ERBB network facilitates KRAS-driven lung tumorigenesis

KRAS oncogene may be another target conquered in non‐small cell lung cancer (NSCLC)

High SHP2 expression determines the efficacy of PD ‐1/ PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung canc

Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.

D‐1553: A novel KRAS^G12C inhibitor with potent and selective cellular and in vivo antitumor activity

Application of plasma circulating <i>KRAS</i> mutations as a predictive biomarker for targeted treatment of pancreatic c

Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells&#x27; Strategic Use of Normal Cellular Mechanisms to Adapt

Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer

Developments in systemic therapies for the management of lung cancer

B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy

Inhibition of yes‐associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model

Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.

SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition

Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells.

ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism

Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells

Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition i

KRAS-targeted therapies in cancer: novel approaches and overcoming resistance

Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice

15 Identification of new combination therapies for lung cancer tumours harbouring KRAS mutations

PO-209 Biological characterisation of specific KRAS mutations: from basic biology to response to treatment

PO-209 Biological characterisation of specific KRAS mutations: from basic biology to response to treatment

Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targe

RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications

Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epi

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small

Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchrono

388 A novel library of optimal affinity KRAS mutation-specific T cell receptors associated with multiple HLAs, in combin

466 Combined inhibition of KRAS G12C and PD-1 boosts the therapeutic efficacy via conditioning of tumor microenvironment

Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance

Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression.

Transfiguring Novel Marine Natural Product as oncogenic KRAS G12C Mutant Inhibitors via

Therapeutics Targeting Mutant KRAS.

Enhancing the Therapeutic Efficacy of KRASG12C Inhibitors in Lung Adenocarcinoma Cell Models by Cotargeting the MAPK Pat

Unlocking New Treatment Possibilities for Metastatic Endometrial Cancer With KRAS G12C Mutation

MEK Inhibition Remodels the Immune Landscape of Mutant <i>KRAS</i> Tumors to Overcome Resistance to PARP and Immune Chec

CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung

Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy

RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wildtype RAS Activatio

CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer

A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial–Mesenchymal Transition, Metastases, and Improves A

Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS

Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cel

Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma

Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy

Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer

The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patient

Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced So

Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal C

Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in t

Data from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically En

Data from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically En

Data from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically En

Data from Anticancer Efficacy of KRAS^G12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical

Data from Anticancer Efficacy of KRAS^G12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical

ERK Inhibitor LY3214996-Based Treatment Strategies for RAS -Driven Lung Cancer

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabl

AZD4625 is a Potent and Selective Inhibitor of KRASG12C

The Next Generation of KRAS Targeting: Reasons for Excitement and Concern

Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered M

AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities f

Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i>

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucl

Dual Inhibitors of KRASG12D and HSP90 are Effective Against KRASG12D Inhibitor Resistance.

Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition.

Abstract A029: Biomarker analysis of patients withMETΔex14 mutated non-small-cell lung cancer (NSCLC) treated with capma

Abstract A084: Use of the natural nucleotide, GTP, is essential for the identification of potent, active-state KRASG12C

Abstract A097: HBI-2438, HUYABIO selective KRASG12C inhibitor with BBB penetration, inhibited tumor growth in a metastat

Abstract A098: HBI-2376, HUYABIO clinical stage SHP2 inhibitor, displays efficacy signal in patients with KRAS mutations

Abstract A099: Best in class, potent, SOS1 inhibitors demonstrate single agent activity in preclinical models of KRAS dr

Abstract A115: mTOR targeting in STK11 deficient Non-Small Cell Lung Cancer (NSCLC): final results, pre-clinical rationa

Abstract A144: HM99462, a Novel &amp; potent SOS1 inhibitor, induces tumor regressions in combination with KRAS G12C inh

Abstract B074: Discovery of MK-1084, a low dose selective clinical stage KRAS G12C inhibitor

Abstract B080: Non-genetic determinants driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant

Abstract B082: A novel, potent and selective ribonucleotide reductase (RNR) inhibitor, BBI-825, blocks extrachromosomal

Abstract B083: Secondary KRAS mutations lead to acquired resistance to KRASG12D inhibitor in colorectal cancer

Abstract B084: Sotorasib/SHP2 inhibitors combo, KRASG12C(ON)I and RASMULTI(ON)I effectively target KRASG12C tumors devel

Abstract B088: VT3989, the first-in-class and first-in-human TEAD auto-palmitoylation inhibitor, enhances the efficacy a

Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the t

Abstract C026: Initial safety, pharmacokinetics, and recommended Phase 2 dose from RAMP 203: A Phase 1/2 study of Avutom

Abstract A048: PRC2 inhibition enhances KRAS inhibitor response to delay treatment relapse in KRAS-mutant preclinical lu

Abstract A066: SOS1-panKRAS modulator, HM101207: A top candidate to control KRAS-MAPK-driven cancers through strong syne

Abstract A080: Systematic PDX-based drug screening reveals genotype-specific vulnerabilities and therapeutic combinatori

Abstract A084: Establishment of KRAS G12C Mutant Brain Metastasis Models for Pre-clinical Evaluation of KRAS G12C Target

Abstract A100: AXL Inhibitor AB801 Increases the Anti-Tumor Efficacy of KRAS Inhibition

Abstract A101: Inhibition of ULK1/2-Mediated Autophagy Enhances Responses to RAS Inhibition and Augments Antigen-Specifi

Abstract B083: Transcription factors enhancing anti-tumor chemokine expression and lymphocyte infiltration in KRAS G12C

Abstract B108: NTS231 is a novel covalent allosteric molecular glue of the KEAP1-CUL3 E3-ligase complex that selectively

Abstract C082: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits

Abstract 2686: The genomic landscape of Kras mutant genetically engineered mouse models of human cancers

Abstract 4342: Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced l

Abstract 1826: Oncogenic KRAS mediates resistance to MET targeted therapy in non-small cell lung cancer (NSCLC) with MET

Abstract 2156: Lung niche factors for progenitor cell self-renewal sustain lung cancer stem cells and contribute to drug

Abstract 938: Detection of actionable mutations in plasma cfDNA samples from patients with non-small cell lung carcinoma

Abstract 1322: Maximizing the therapeutic potential of SHP2 inhibition with rational combination strategies in tumors dr

Abstract 2797: Accumulation of neutrophils in the tumor microenvironment promotes resistance to immunotherapy in pancrea

Abstract 4980: Altered pan-Ras pathway and activating mutations in EGFR result in elevated CD73 in multiple cancers

Abstract 1091: BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with

Abstract 1943: SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by o

Abstract 1958: Repotrectinib increases effectiveness of KRAS-G12C inhibitors inKRAS-G12Cmutant cancer modelsviasimultane

Abstract 5684: Drug-anchoredin vitroandin vivoCRISPR screens to identify targetable vulnerabilities and modifiers of res

Abstract LB-122: Combinations of SHP2 inhibitor to overcome RAS activation by receptor tyrosine kinases in response to E

Abstract 1104: Repotrectinib increases effectiveness of MEK inhibitors in KRAS mutant cancer models

Abstract 1263: Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS-G12C inhibitors through a vertical pat

Abstract 1342: Development and preclinical evaluation of unique first-in-class small molecule inhibitors of the anti-apo

- **DOI:** 10.1158/1538-7445.am2021-1425 - **Authors:** S. Coma, J. Paradis, J. Gutkind, J. Pachter - **Year:** 2021 - *

Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactini

Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibit

Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

Abstract 1101: CTNNB1 mutation can mediate resistance to EGFR, ALK and KRAS targeted therapies

Abstract 1105: MET or SHP2 inhibition enhances targeted therapies and delays the emergence of resistance in oncogene-dri

Abstract 1107: Notch activation drives resistance to Kras(G12C) inhibition in lung adenocarcinoma

Abstract 1131: Pharmacogenomic insight into targetable vulnerabilities and modifiers of response to MRTX1133 in KRASG12D

Abstract 1300: Targeted therapies prime lung cancer cells for macrophage-mediated destruction

Abstract 1352: In vivo CRISPR screening identifies mediators of immune evasion in KRAS-mutant lung cancer

Abstract 3101: Evaluation of novel therapeutic strategies for KRAS mutated NSCLC patients using our own collections of P

Abstract 3110: Identification of the phosphorylation network in PDX and corresponding organoid (PDXO) models upon target

Abstract 3255: Probing and overcoming KRASG12C inhibitor resistance by combination with a pan-KRAS SOS1 inhibitor

- **DOI:** 10.1158/1538-7445.am2022-338 - **Authors:** S. García-Román, M. Molina-Vila, E. D&#x27;hondt, R. Rosell - **Y

Abstract 3600: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with the KRASG

Abstract 4029: Combination of KRASG12C(ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumor imm

Abstract 402: Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS G12C inhibitors through vertical inhibi

Abstract 5233: Evolution of therapy resistance through acquired KRAS amplification in ROS1 fusion KRAS G12C double posit

Abstract 5313: A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mut

Abstract 5463: BPI-442096: A potent and selective inhibitor of SHP2 for the treatment of multiple cancers

Abstract 6121: Correlation of tumor immune microenvironment status and driver genes alterations in Chinese non-small-cel

Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-m

Abstract CT202: A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in

Abstract CT204: A phase 1/2 study of VS-6766 in combination with sotorasib in patients with KRAS G12C mutant non-small c

Abstract CT515: A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring KRAS or EGFR mutation

Abstract 1034: Clinical utility of liquid biopsy for molecular characterization and resistance detection in patients wit

Abstract 1072: Combination of 5-Fluorouracil or ONC212 plus KRAS G12D inhibitor MRTX1133 against colorectal and pancreat

Abstract 1079: Combination of tipifarnib with KRAS G12C inhibitors to prevent adaptive resistance

Abstract 1142: Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C

Abstract 1386: Ag5 is highly potent, mitochondrially targeted agent with a differentiated mechanism of action that promi

Abstract 1677: ASPC-1-MRTX-1133R as a useful cell line model for KRAS-G12D inhibitor development

Abstract 1682: Bridging gaps in treatment resistance 2D models with the incorporation of 3D models

Abstract 185: Global mapping of pathway modules and phosphorylation networks in PDX and corresponding organoid (PDXO) mo

Abstract 257: CDX model based genome-scale CRISPR KO screens for modulators of KRAS (G12C) inhibitor sensitivity

Abstract 2621: Characterizing MEK1/2 degradation in K-ras mutant cells

Abstract 2790: Preclinical studies of ZG19018, a novel irreversible covalent inhibitor of KRAS G12C, for the treatment o

Abstract 2805: Pharmacogenomic platform using patient-derived cells to delineate tumor heterogeneity and therapeutic res

Abstract 3839: Discovery of GSTZ1 as a novel target for drug refractory non-small cell lung cancer by using fragment-bas

Abstract 3867: Chromatin modification driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant no

Abstract 3871: KRAS G12C mutant allele amplification drives resistance to sotorasib in vitro

Abstract 3878: Targeting Hippo-YAP, BRD4 and RAS-MAPK interplay in lung cancer to forestall drug resistance

Abstract 3907: Targeting adaptive resistance to EGFR and KRAS G12C inhibitors by TT125-802, a novel and specific CBP/p30

Abstract 3971: Developing cancer cell based in vitro and in vivo models with CRISPR-mediated knock-in technology for ant

Abstract 412: Drug combination screen identifies pemigatinib, an FGFR inhibitor, as a mechanism to overcome KRASG12C inh

Abstract 4155: The RAF/MEK clamp avutometinib (VS-6766) induces an immunogenic tumor microenvironment and potentiates th

Abstract 429: Efficacy of JSI-1187 or VIC-1911 in combination with KRAS G12C inhibitors for the treatment of KRAS G12C-m

Abstract 486: Characterization of a novel series of highly selective PARP7 inhibitors

Abstract 4984: Integrated platform enables KRAS-targeted drugs discovery

Abstract 5484: Synergistic antitumor activity of nab-sirolimus in combination with KRAS inhibitors (KRASis) sotorasib an

Abstract 5501: Vertical inhibition of the MAPK pathway with D3S-002, a potent and selective ERK1/2 inhibitor, to improve

Abstract 5739: Targeting WEE1 to improve the therapy of KRAS G12C mutant non-small cell lung cancer

Abstract 5973: The brain penetrant CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted the

Abstract 6570: Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer

Abstract 6691: Paired comparison of routine molecular screening of patient samples with advanced non-small cell lung can

Abstract 940: Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer

Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patien

Abstract LB231: Overcoming KRAS G12C inhibitor resistance with a chaperone-mediated protein degrader (CHAMP)

Abstract 1212: Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC

Abstract 1669: KRAS G12X mutants display differential preferences in downstream effector binding

Abstract 1926: MRAS the forgotten member of the GTPase superfamily plays a role in KRASG12Ci resistance

Abstract 1927: Resistance to RAS-GTP inhibition in models of pancreatic ductal adenocarcinoma arises downstream of RAS e

Abstract 1928: Targeting FAK to improve the therapy of KRAS G12C mutant cancers

Abstract 1929: Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition a

Abstract 1931: Targeting YAP1/TEAD signaling re-sensitizes MAPK/ERK pathway inhibitors in KRAS- driven cancer cells

Abstract 1932: Overcoming acquired resistance to KRAS(G12D) inhibition using a KRAS-HSP90 hetero-bifunctional small mole

Abstract 1933: Dissecting acquired resistance to KRASG12D inhibition in a mouse model of pancreatic ductal adenocarcinom

Abstract 1935: The FAK/SRC axis mediates resistance to KRAS G12C inhibitors and its blockade can overcome KRAS inhibitor

Abstract 1936: KEAP1-NRF2 mediated resistance against KRASG12D inhibitor in pancreatic ductal adenocarcinoma

Abstract 1938: WEE1 inhibition prevents and overcomes resistance to KRAS inhibitors in lung cancer by enhancing MCL1-med

Abstract 1940: Identifying resistant mechanisms to direct KRAS inhibitors in NSCLC

Abstract 1942: Characterization of a panel of CRISPR/Cas9 engineered KRAS G12C inhibitor-resistant tumor models

Abstract 1943: Discovery and characterization of potential drivers of resistance to the KRAS G12D inhibitor, MRTX1133, i

Abstract 1944: Using patient-derived cancer organoids to determine the effects of the anti-EGFR therapy panitumumab in t

Abstract 1945: Mechanisms of acquired resistance to EGFR tyrosine kinase inhibitor osimertinib and KRAS-G12C inhibitor s

Abstract 1946: Elucidating the mechanisms of acquired resistance to AMG510 in cancer models harboring KRAS G12C mutation

Abstract 1947: Studies on pMEK inhibitors for the treatment of RAS-mutant cancers as a single agent or combinations

Abstract 2101: Patient-derived cells (PDCs) and organoids (PDOs) as critical platforms for developing next therapeutic s

Abstract 2494: RAS-Bio a unique pan-cancer biobank for RAS-driven tumors

Abstract 2499: Window-of-opportunity trial of metastatic pancreatic cancer reveals potential mechanisms of response to t

Abstract 2817: Establishment of KRAS G12C mutant brain metastasis models for pre-clinical evaluation of KRAS G12C target

Abstract 3313: Discovery of a potent, selective, and orally available small molecule for disruption of the SOS1-RAS inte

Abstract 3321: KRASmulti inhibitor BI 3706674, an orally bioavailable, direct inhibitor of diverse oncogenic KRAS varian

Abstract 4322: Inhibition of ULK and KRASG12C control tumor growth in preclinical models of lung cancer

Abstract 447: Anti-tumor efficacy of ompenaclid, a creatine transporter inhibitor, in KRAS mutant tumors, including NSCL

- **DOI:** 10.1158/1538-7445.am2024-5948 - **Authors:** Yan Wang, Richard M. Neve, J. Staunton, Kevin R. Webster - **Yea

Abstract 6049: Cell-based PROTAC screening for cancer drug discovery

Abstract 617: BH-30236, a novel macrocyclic CLK inhibitor modulating RNA splicing, demonstrates potent inhibition of can

Abstract 6496: Assessment of tyrosine kinase inhibitor bypass mechanisms in lung cancer using single cell multiomics, pa

Abstract 657: Discovery of a novel brain penetrant SHP2 allosteric inhibitor with anti-tumor effects

Abstract 6584: Aberrant TRIM7 expression potentiates RACO-1 mediated proliferation and dysregulated interferon responsiv

Abstract 6585: Combination RASG12C(ON) and RASMULTI(ON) inhibition overcomes resistance and prolongs durability in precl

Abstract 6909: KRASG12C inhibitor resistance in patient-derived non-small cell lung cancer models

Abstract CT117: A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patient

Abstract CT119: Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (

Abstract CT246: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lun

Abstract LB266: AMG510-mediated inactivation of BCL-xL protein promotes Gasdermin-E-dependent pyroptosis in KRAS-G12C mu

Abstract LB428: Discovery of KY-001:A Direct Inhibitor of TEAD-YAP Protein-Protein Interaction for the Treatment of Adva

Abstract LB451: Targeting oncogenic transcription and signaling crosstalk fueling drug resistance in lung cancer

Abstract 1276: UNLOCK, a preclinical platform of PDX models resistant to innovative therapies

Abstract 239: RCZY-690 and RCZY-680: Novel, highly potent, and orally bioavailable, tri-complex pan RAS-MULTI(ON) inhibi

Abstract 2766: Metabolic and tumor immune cell landscapes are significantly different amongst KRAS mutational variants i

Abstract 27: Orthotopic tumor models using luciferized patient-derived organoids for investigating EGFR-MAPK pathway inh

Abstract 3706: Identifying first-in-class targets for anti-cancer therapy in KRAS mutant NSCLC using the systems biology

Abstract 3882: Patterns of genomic patient-model conservation and evolution in the Human Cancer Models Initiative (HCMI)

- **DOI:** 10.1158/1538-7445.am2025-419 - **Authors:** Dingcheng Gao, Yingzhuo Liu, Yi Ban - **Year:** 2025 - **Journal:

Abstract 421: Targeting WEE1 enhances the antitumor effect of KRAS mutated non-small cell lung cancer harboring TP53 mut

Abstract 422: Aurora kinase A inhibition overcome adaptive resistance to KRAS G12C inhibitor by replication stress-induc

Abstract 4371: PHI-501 as a potent pan-RAF/DDRs inhibitor suppresses lung cancer cell proliferation and overcomes KRAS G

Abstract 4434: Ficerafusp alfa reverses acquired resistance to the KRAS-G12C inhibitor sotorasib in KRAS-G12C-mutated lu

Abstract 4450: Targeting KEAP1/NRF2 signaling sensitizes KRAS-driven NSCLC to KRAS inhibitors

Abstract 4559: Paired liquid biopsies analysis reveals resistance mechanisms and prognostic factors in patients treated

Abstract 4714: Elucidating mechanisms of acquired resistance to mobocertinib in non-small cell lung cancer harboring EGF

Abstract 5329: Development of a novel selective CDK4 inhibitor for HR+/HER2- breast cancer

Abstract 534: Sotorasib-resveratrol combination induces synergistic cytotoxicity by downregulating K-RAS signaling in K-

Abstract 5501: An integrated end-to-end platform facilitating the evaluation of next generation KRAS inhibitors

Abstract 5507: Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancer

Abstract 5509: Mechanisms regulating resistance to KRAS inhibitor driven by DNp63/YAP regulation of tissue stiffness and

Abstract 5512: Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance dr

Abstract 5517: Overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC by TUSC2 gene therapy

Abstract 5518: Targeting FAK by Ifebemtinib synergizes with Pan RAS inhibitors in treating RAS mutant cancers

Abstract 5521: Integrative analysis of acquired drug resistance to KRAS(G12D) inhibitors

Abstract 5522: Cell state modulates the KRASG12C proximal proteome

Abstract 5524: Developing KRASG12C inhibitor-resistant tumor models for efficacy evaluation of next-generation anticance

- **DOI:** 10.1158/1538-7445.am2025-5532 - **Authors:** Hayato Kawachi, Tadaaki Yamada, Yuki Katayama, Takayama Koichi -

Abstract 5706: A patient-derived organoid screening platform as a powerful tool to study efficacy of KRAS inhibitors

Abstract 5836: Suppression of TNFα and IFNγ signaling are key molecular events in KRASG12C mutant cancer cells to confer

Abstract 6376: KRASmultidegrader BPI-585725 displays potent anti-tumor activity in KRAS-driven preclinical models

Abstract 6997: Impact of KRASG12C oxidation state on non-small-cell lung cancer response to targeted therapeutics

Abstract CT073: A first-in-human study of oral TNO155 (batoprotafib) alone and in combination with EGF816 (nazartinib) i

Abstract CT138: Safety and efficacy of HS-10370 in KRAS G12C-mutated advanced solid tumors: Updated results from phase 1

Abstract CT209: Adagrasib (ADA) as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)

Abstract CT266: D3S-001, a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in KRAS G12C inhibitor resistan

Abstract LB290: Identifying novel mechanisms of resistance to KRAS-inhibitors in NSCLC

Abstract ND01: AMG 410: An H/NRAS-sparing pan-KRAS inhibitor with dual GTP(on)/GDP(off)-state activity for the treatment

Abstract IA24: Interrogating therapy response and resistance in engineered preclinical models

Abstract B016: Inhibition of KRASG12C in colon cancer illustrates a link between beta-catenin, WNK, and the GID complex

Abstract B013: Precision medicine platform to guide the treatment of NSCLC

Abstract PR009: Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer

Abstract I16: KRAS and environmental signals regulate MYC to drive lineage plasticity, pancreas cancer progression, and

Abstract C097: KRASG12C exhibits allele-specific biology in pancreatic cancer and targeting CD24 sensitizes KRASG12C-dri

Abstract C116: Oncogenic Kras signaling shapes the tumor microenvironment in lung adenocarcinoma

Abstract C067: Understanding the tumor extrinsic role of oncogenic Kras in pancreatic cancer

Abstract IA-04: Targeting the oncogenic state of RAS with tri-complex inhibitors

Abstract IA-05: Targeting KRAS for pancreatic cancer treatment

- **DOI:** 10.1158/1538-7445.pancreatic25-a095 - **Authors:** Donovan Drouillard, Marissa Davies, Donna McCallister, Mic

Abstract B083: Defining a molecular basis and therapeutic approach for KEAP1-NRF2 mediated resistance to KRAS inhibition

Abstract B092: Investigating combination therapies to overcome RAS inhibitor resistance in pancreatic cancer

- **DOI:** 10.1158/1538-7445.pancreatic25-ia02 - **Authors:** Mallika Singh - **Year:** 2025 - **Journal:** Cancer Resea

Targeted therapies in non-small cell lung cancer: present and future

Abstract B011: RNA-based therapeutics to target the p53 pathway in cancer

Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and

Abstract B23: Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257: A prototype selective inh

Abstract IA19: Insight towards therapeutic susceptibility of KRAS-mutant cancers from MRTX1257, a novel KRAS G12C mutant

Abstract A001: RAS:RAF proximity ligation assay may predict response to KRASG12C inhibitors in NSCLC

Abstract A017: Deciphering the role of integrated stress response (ISR) in the developmental stages of mutant KRAS lung

Abstract B004: Multi-omics profiling to identify mechanisms of resistance to KRAS inhibition: A comparative study on col

Abstract B012: Effects of adagrasib on oncogenic signaling, immune cell regulation and biomarkers of response in prelimi

Abstract B025: The RAF/MEK clamp avutometinib (VS-6766) enhances antitumor efficacy of KRAS G12C and G12D inhibitors thr

Abstract B026: Overcoming KRAS G12C inhibitor resistance with chaperone-mediated protein degrader in NSCLC

- **DOI:** 10.1158/1557-3125.ras23-ia06 - **Authors:** C. Der - **Year:** 2023 - **Journal:** Molecular Cancer Research

Abstract IA07: Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer

Abstract IA20: The impact of RAS inhibition on tumor immune evasion

Abstract PR07: Oncogenic Kras signaling shapes the tumor microenvironment in lung adenocarcinoma

Abstract B30: Three-dimensional organoid model for acquired drug resistance in non-small cell lung cancer

Data from EGFR Blockade Reverts Resistance to KRAS^G12C Inhibition in Colorectal Cancer

EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer.

Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in non-small-cel

Mechanisms of Resistance to KRASG12C-Targeted Therapy.

Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies

Emerging Trends in Cancer Drug Discovery—From Drugging the “Undruggable” to Overcoming Resistance

Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Altera

The gRASs Is Greener: Potential New Therapies in Lung Cancer with Acquired Resistance to KRASG12C Inhibitors.

Can Drug Repurposing Accelerate Precision Oncology?

Classification of KRAS -Activating Mutations and the Implications for Therapeutic Intervention

Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC.

Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway wi

Mechanisms of KRAS Inhibitor Resistance Revealed.

Multiple Mechanisms Underlie the Acquired Resistance to KRAS G12C Inhibition.

Abstract B029: Investigating therapeutic strategies to promote immune rejection of KRAS G12C inhibitor-resistant sub-pop

Data from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 In

Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical

N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung

Synergy of EGFR and AURKA Inhibitors in KRAS -mutated Non–small Cell Lung Cancers

The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Mo

Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JA

Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor

Sotorasib Shows Intracranial Activity in Patients with <i>KRAS G12C-</i> Mutated Adenocarcinoma of the Lung and Untreate

Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report

Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomati

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas

Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current dev

New developments in targeted therapy for metastatic colorectal cancer

Pan-RAS Inhibitor RMC-7977 Overcomes Oncogenic RAS Signaling and Exerts Antileukemic Effects in CMML/AML Cells

Biological therapies in nonsmall cell lung cancer

Applications of CRISPR technology to lung cancer research

Personalised medicine for nonsmall cell lung cancer

KRAS oncogene in lung cancer: focus on molecularly driven clinical trials

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer

Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guid

New KRAS Inhibitor Induces Responses in Non&amp;amp;#x2013;Small Cell Lung Cancer With &amp;lt;em&amp;gt;KRAS G12C&amp;l

Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel

Overcoming KRAS-Mutant Lung Cancer.

Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer

MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint bloc

Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecul

Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120.

Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blocka

Molecular characterization and management of secondary resistance to serial TRK inhibitors.

Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS –mutated non-small cell lung cancer (NSC

Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular

Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRAS G12C inhibitor, in combination with oth

Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung ca

Genomic landscape of non-small cell lung cancer (NSCLC) with methylthioadenosine phosphorylase (MTAP) deletion.

Molecular profiling by NGS upon progression disease in advanced stage NSCLC patients.

A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.

Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.

Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and

Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A ph

A phase 2 study of VS-6766 (RAF/MEK clamp) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor

A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C m

Early assessment of sotorasib for treatment of patients with advanced non-small cell lung cancer using real-world data i

The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in

KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer

Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with

Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced K

A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-

RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small c

FDA analysis of toxicity profiles of oral TKIs recently approved for non-small cell lung cancer based on receipt of prio

Analysis of survival outcomes in patients with non–small-cell lung cancer with mutations in STK11/LKB1 receiving chemoim

First-in-human study of ZG19018, targeting KRAS G12C, as monotherapy in patients with advanced solid tumors.

Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant.

SPARK, studying pathways of resistance in KRAS-driven cancers: A remote plasma ctDNA participation study to identify mec

ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage I

KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in pa

Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer

A unique model: Partnership between community oncology and pharma for clinical trial enrichment.

Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12

Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) i

Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC)

Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pemb

Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK

Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC).

Gene expression correlates of adagrasib response in KRASG12C mutated non-small cell lung cancer (NSCLC).

Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRASG12C mutation: A phase 1b study.

Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutan

Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C m

Final analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with

KRAS mutation subtypes responded differently to combination immunotherapy via disturbing myeloid-derived suppressor cell

Next-generation sequencing in patients with lung cancer undergoing immunotherapy: Retrospective analysis.

Effect of targeting FAK by ifebemtinib and immunogenic cell death of Kras G12C/G12D inhibition on the efficacy of PD1 bl

Characterization of BTX-10908, a first-in-class, orally bioavailable SOS1 bifunctional degrader for the treatment of KRA

Phase 1/2 study of FMC-376 an oral KRAS G12C dual inhibitor in participants with locally advanced unresectable or metast

SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemother

Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic

KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in p

Quantitative evaluation of oncogenic KRAS signaling and therapeutic effects of molecular-targeted drugs in living cells

Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally

Initial results of a screening trial for evaluating oncogenic drivers in Japanese patients with surgically resected earl

First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRAS G12C -mutated non

S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent KRAS G1

Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with

MK-1084 for KRAS G12C-mutated (mut) metastatic non–small-cell lung cancer (mNSCLC): Results from KANDLELIT-001.

Safety and efficacy of ifebemtinib (IN10018) combined with garsorasib (D-1553) in KRAS G12C mutant solid tumors from a p

Prediction of sotorasib response duration and identification of clinically actionable resistance mechanisms using an RNA

Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8

Krascendo 2: A phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previou

Spatially resolved protein profiling in pancreatic adenosquamous carcinoma.

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Smal

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With <i>KRAS^G12C</i>-Mutated Non–Smal

Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation

Clinical utility of upfront liquid biopsy in non-small cell lung cancer in the community setting.

Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in Advanced Non–Small-Cell Lung Cancer

Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Ins

Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced <i>

Molecular inhibition of RAS signalling to target ageing and age-related health

Computational Screening of Marchantia polymorpha Against KRAS G12C Mutation in Non-Small Cell Lung Cancer

Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report.

Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.

Biomarkers in the management of lung cancer: changing the practice of thoracic oncology

Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospecti

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer

Emerging Therapeutic Implications of STK11 Mutation: Case Series.

Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown

Genome editing of LKB1 (STK11) mutation in A549 lung cancer cells using CRISPR/Cas9 system

Intracranial efficacy of adagrasib in patients with KRAS G12C mutated non-small cell lung cancer (NSCLC): are results KR

Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies

Emerging application of genomics-guided therapeutics in personalized lung cancer treatment

Abrogation of ARF6 in promoting erastin-induced ferroptosis and mitigating capecitabine resistance in gastric cancer cel

Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy

Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival

ATR expression as a prognostic biomarker in KRAS-mutated non-small cell lung cancer

The efficacy and predictive factors of first-line immune checkpoint inhibitors for advanced non-small cell lung cancer w

Intratumoral and intertumoral heterogeneity drives EGFR treatment considerations

Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted th

Adagrasib in the treatment of KRASG12C-mutated non-small cell lung cancer: a cost-effectiveness analysis.

KRAS and EGFR inhibitors: a new step in the management of colorectal cancer

Non-small cell lung cancer: current treatment and future advances

KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients

Autochthonous murine models for the study of smoker and never-smoker associated lung cancers

Future perspectives from lung cancer pre-clinical models: new treatments are coming?

KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples

Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immu

Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcino

Immunotherapy in oncogene addicted non-small cell lung cancer

Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing—a single-center expe

A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small ce

Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer

KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receivin

The relationship between different subtypes of KRAS and PD-L1 &amp; tumor mutation burden (TMB) based on next-generation

KRAS G12C mutation: from undruggable target to potentially agnostic biomarker

Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentatio

Immune status and combined immunotherapy progression in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant tumors.

Molecular characterization of acquired resistance to KRAS G12C inhibition in gastrointestinal cancers

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.

Recent Advancement in Drug Targeting Therapies in the Treatment of Pancreatic Cancer.

Recent developments, challenges and opportunities in targeting the KRAS pathway

Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer.

Targeted Degradation of Oncogenic KRASG12C by VHL-recruiting PROTACs

Mutation status and postresection survival of patients with non–small cell lung cancer brain metastasis: implications of

Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer

Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness

RAS: Striking at the Core of the Oncogenic Circuitry

Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer

miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential

Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemist

KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges

Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways

[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)].

[Annual therapeutic advances in advanced non-small cell lung cancer in 2024].

[Current status and outlook of medical treatment for KRAS-mutated non-small cell lung cancer].

Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma

Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology

Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer

Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

PCR-based detection of EGFR, ALK, KRAS and BRAF mutations in Russian patients with lung adenocarcinoma: a single-center

Efficacy and immune modulation of KRAS G12C inhibitor sotorasib in murine KRAS G12C mutant non-small cell lung cancers w

Tumour-Derived Extracellular Vesicles in Chemotherapy Resistance: Molecular Pathways, Clinical Implications and Therapeu

Advances in Targeted Therapies for Non-Small Cell Lung Cancer: Current Trends and Challenges

KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.

New Targeted Therapies for Metastatic Non–Small Cell Lung Cancer

Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer

Lung Cancer in the Era of Precision Oncology

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

[Current Status and Future Perspectives of Molecular Targeted Therapies for Lung Cancer].

COMBINATION WITH BCA101 IMPROVES THE EFFICACY OF KRAS-G12C INHIBITOR AND OVERCOMES G12C INHIBITOR-INDUCED RESISTANCE IN

Drug Targets for Overcoming Resistance to KRAS G12C Inhibitors (G12Cis) in Cancer